Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. - Wikidata - awgldk - TriplyDB

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.

http://www.wikidata.org/entity/Q37737863

about

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.

http://www.wikidata.org/entity/Q37737863

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 April 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Off-target effects and clinica ...... rafenib: The TRIBUTE analysis.

@en

Off-target effects and clinica ...... rafenib: The TRIBUTE analysis.

@nl

type

label

Off-target effects and clinica ...... rafenib: The TRIBUTE analysis.

@en

Off-target effects and clinica ...... rafenib: The TRIBUTE analysis.

@nl

prefLabel

Off-target effects and clinica ...... rafenib: The TRIBUTE analysis.

@en

Off-target effects and clinica ...... rafenib: The TRIBUTE analysis.

@nl

P1433

Q37737863-98614D15-E116-4876-B99C-15D9199CD614

P1476

Q37737863-F3A14965-45B2-4586-913E-D57994180D8C

P2093

Q37737863-048DE285-1064-4DF3-AAA5-16E1CE9F847C

Q37737863-15FED75C-6828-4696-9FD2-0FBB3DD36C21

Q37737863-1B37B6E3-04F3-48E0-BDB1-1DB4EC86460D

Q37737863-1C351762-4B8F-416A-94CD-372883586DE7

Q37737863-1C53C00F-7EA3-4ACE-8146-00B8821FAED2

Q37737863-1FC40E99-3E60-4B85-AD35-3462B900F0A8

Q37737863-2419C8E0-286D-4AE0-982F-145C720BA4DE

Q37737863-4F7E0BFB-B0A5-4331-9D35-1D70EE9A00B2

Q37737863-5317E3BF-BBA4-4B31-8059-C6E594BC9CDA

Q37737863-60590F68-9A8A-4659-83E1-470DB3130E17

P2860

Q37737863-03E3C9AF-702B-44A2-8AF1-B6DC08C26FE7

Q37737863-08D3BEDF-AC45-493E-958B-8C1255FC35F3

Q37737863-1270E844-81D6-490E-AD77-90798658F86E

Q37737863-20BA47E2-0C80-4A22-B680-BB3C6A76975F

Q37737863-27AC3708-EAB7-4C1F-933B-C1C0DE41278E

Q37737863-36172EBE-B9FD-4DF3-9B9A-BABA7E9757AE

Q37737863-38C083F5-7740-4056-87AB-D3C99987F800

Q37737863-51644E50-ABA5-4E04-A6CE-7B47E35B22A7

Q37737863-6B7DF43C-6317-4EF4-9D97-4D2DDCF164A2

Q37737863-78DAF4B5-D71B-4534-AD05-75BF05BB9B15

P2888

Q37737863-BFF6E76A-005A-4850-B66A-A33DD6E07FD6

P304

Q37737863-BDB9AD96-AB04-474D-B7BD-D89D8745F36A

P31

Q37737863-0CBCC8C3-5539-48C8-87FE-0C2A804DA815

P356

Q37737863-DFCAEF6F-6ECE-4132-B3FE-6B9A233999F4

P407

Q37737863-C8BB1E43-E0A8-4BB0-8DB2-36B9FE58FA09

P478

Q37737863-F846CDF0-8863-4FD9-8B99-B875D6AF80CC

P50

Q37737863-40717299-3F96-4F55-BB38-D879A54958B5

Q37737863-83D7F5B5-DEB4-456D-9AE9-3DA9A242F313

P577

Q37737863-D6BE4315-0015-4D5B-A744-D3EEA45A3C08

P698

Q37737863-604E0926-58CE-4709-BE3F-5D7EDF2023F9

P921

Q37737863-220833C9-B75F-4D53-A9B0-D37D26B65148

P932

Q37737863-C0EF0C7F-1630-4915-B630-A31CC8D5E5C3

P356

P1433

Scientific Reports

P1476

Off-target effects and clinica ...... rafenib: The TRIBUTE analysis.

@en

P2093

Alberto Zaniboni

http://www.w3.org/2001/XMLSchema#string

Anna Maria Lanzillo

http://www.w3.org/2001/XMLSchema#string

Elena Maccaroni

http://www.w3.org/2001/XMLSchema#string

Fabiana Pani

http://www.w3.org/2001/XMLSchema#string

Maria Giuditta Baleani

http://www.w3.org/2001/XMLSchema#string

Mario Scartozzi

http://www.w3.org/2001/XMLSchema#string

Michela Del Prete

http://www.w3.org/2001/XMLSchema#string

Riccardo Giampieri

http://www.w3.org/2001/XMLSchema#string

Roberta Mascia

http://www.w3.org/2001/XMLSchema#string

Rossana Berardi

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib

Management of regorafenib-related toxicities: a review

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.

P2888

P304

45703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP45703

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Stefano Cascinu

P577

2017-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28378839

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5380985

http://www.w3.org/2001/XMLSchema#string